Tony Deng

Fully licensed physician with Texas Medical Board with experience working in anesthesiology and internal medicine.
Fully licensed equity research analyst (Series 7, 63, 86, 87) with coverage of 8 SMID biotech companies.

Credit Suisse Securities, Associate (Full-Time), 2021 – Present
 Compiled research findings into initiation reports for 4 SMID Cap biotechnology companies and 1 industry deck
 Synthesized research findings into 2 deep dive reports for insights into POS of trials and treatment landscapes
 Provided updates to investors via 15 weekly notes and 37 notes in response to news, earnings, and other updates
 Conducted due diligence for vetting of 2 pre-IPO biotechnology companies
 Consulted corporate management and key opinion leaders in to develop insights into covered companies
 

University of Texas Medical Branch, Resident Physician, Anesthesiology (Full-Time), 2020 –2021
 Managed patients in 7 settings: internal medicine, outpatient pain, ICU, cardiology consults, and OR anesthesiology
 Developed quality improvement practice of standardized questionnaires to expedite outpatient staffing
 Coordinated with social workers regarding plans for compliance and follow-up of hospitalized patients after discharge

University of Texas Medical Branch, Galveston, TX, Doctor of Medicine, 2016 –2020
 GPA: n/a. MCAT 33/45 (91st percentile)
University of California Berkeley, Berkeley, CA, B.A. Integrative Biology, 2014 –2015
 cGPA 3.96/4.00. SAT: 2340 (99th percentile)